These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

380 related articles for article (PubMed ID: 23714495)

  • 1. Peritoneal mesothelioma: the site of origin matters.
    Kindler HL
    Am Soc Clin Oncol Educ Book; 2013; ():182-8. PubMed ID: 23714495
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Malignant Peritoneal Mesothelioma: Treatment Options and Survival.
    Salo SAS; Ilonen I; Laaksonen S; Myllärniemi M; Salo JA; Rantanen T
    Anticancer Res; 2019 Feb; 39(2):839-845. PubMed ID: 30711965
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First-line chemotherapy with pemetrexed plus cisplatin for malignant peritoneal mesothelioma.
    Fujimoto E; Kijima T; Kuribayashi K; Negi Y; Kanemura S; Mikami K; Doi H; Kitajima K; Nakano T
    Expert Rev Anticancer Ther; 2017 Sep; 17(9):865-872. PubMed ID: 28594258
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Malignant Mesothelioma and Its Non-Asbestos Causes.
    Attanoos RL; Churg A; Galateau-Salle F; Gibbs AR; Roggli VL
    Arch Pathol Lab Med; 2018 Jun; 142(6):753-760. PubMed ID: 29480760
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 50 Patients with Malignant Mesothelioma of Both the Pleura and Peritoneum: A Single-Institution Experience.
    Letica-Kriegel AS; Leinwand JC; Sonett JR; Gorenstein LA; Taub RN; Chabot JA; Kluger MD
    Ann Surg Oncol; 2020 Jan; 27(1):205-213. PubMed ID: 31065962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of Treatment Strategies and Outcomes in Malignant Peritoneal Mesothelioma: Insights From a Multi-Center Study.
    Yaşar S; Yılmaz F; Utkan G; Algın E; Bayram D; Tamam S; Öksüzoğlu ÖBÇ; İlhan A; Erdat EC; Ünal AE; Yalçın Ş
    Ann Surg Oncol; 2024 Sep; 31(9):6228-6236. PubMed ID: 38806763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Well-differentiated papillary mesothelioma: clustering in a Portuguese family with a germline BAP1 mutation.
    Ribeiro C; Campelos S; Moura CS; Machado JC; Justino A; Parente B
    Ann Oncol; 2013 Aug; 24(8):2147-50. PubMed ID: 23585512
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Statement on malignant mesothelioma in the United Kingdom.
    British Thoracic Society Standards of Care Committee
    Thorax; 2001 Apr; 56(4):250-65. PubMed ID: 11254815
    [No Abstract]   [Full Text] [Related]  

  • 9. Multicystic and diffuse malignant peritoneal mesothelioma in children.
    Vermersch S; Arnaud A; Orbach D; Andre N; Berger C; Kepenekian V; Brigand C; Fresneau B; Poli-Merol ML; Habougit C; Varlet F; Scalabre A
    Pediatr Blood Cancer; 2020 Jun; 67(6):e28286. PubMed ID: 32277799
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Malignant peritoneal mesothelioma.
    Loggie BW
    Curr Treat Options Oncol; 2001 Oct; 2(5):395-9. PubMed ID: 12057102
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Malignant Peritoneal Mesothelioma: National Practice Patterns, Outcomes, and Predictors of Survival.
    Verma V; Sleightholm RL; Rusthoven CG; Koshy M; Sher DJ; Grover S; Simone CB
    Ann Surg Oncol; 2018 Jul; 25(7):2018-2026. PubMed ID: 29721724
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant dendritic cell based immunotherapy (DCBI) after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma, a phase II single centre open-label clinical trial: rationale and design of the MESOPEC trial.
    de Boer NL; van Kooten JP; Burger JWA; Verhoef C; Aerts JGJV; Madsen EVE
    BMJ Open; 2019 May; 9(5):e026779. PubMed ID: 31092657
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complete clinical remission of malignant peritoneal mesothelioma with systemic pemetrexed and bevacizumab in a patient with a BAP1 mutation.
    Lee J; Turetsky J; Nasri E; Rogers SC
    BMJ Case Rep; 2023 Dec; 16(12):. PubMed ID: 38142057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical characteristics of patients with malignant pleural mesothelioma harboring somatic BAP1 mutations.
    Zauderer MG; Bott M; McMillan R; Sima CS; Rusch V; Krug LM; Ladanyi M
    J Thorac Oncol; 2013 Nov; 8(11):1430-3. PubMed ID: 24128712
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diffuse malignant peritoneal mesothelioma: Evaluation of systemic chemotherapy with comprehensive treatment through the RENAPE Database: Multi-Institutional Retrospective Study.
    Kepenekian V; Elias D; Passot G; Mery E; Goere D; Delroeux D; Quenet F; Ferron G; Pezet D; Guilloit JM; Meeus P; Pocard M; Bereder JM; Abboud K; Arvieux C; Brigand C; Marchal F; Classe JM; Lorimier G; De Chaisemartin C; Guyon F; Mariani P; Ortega-Deballon P; Isaac S; Maurice C; Gilly FN; Glehen O;
    Eur J Cancer; 2016 Sep; 65():69-79. PubMed ID: 27472649
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Malignant peritoneal mesothelioma. Our experienced with triple combined therapy: cytoreduction, intraperitoneal perioperative chemotherapy and hyperthermia].
    Gómez Portilla A; Cendoya I; Muriel J; Olabarria I; Guede N; Moraza N; Fernández E; Martínez de Lecea C; Magrach L; Martín E; Romero E; Aguado I; Valdovinos M; Larrabide I
    Cir Esp; 2007 Feb; 81(2):82-6. PubMed ID: 17306123
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Iterative cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent or progressive diffuse malignant peritoneal mesothelioma: clinicopathologic characteristics and survival outcome.
    Ihemelandu C; Bijelic L; Sugarbaker PH
    Ann Surg Oncol; 2015 May; 22(5):1680-5. PubMed ID: 25120250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Malignant Peritoneal Mesothelioma: Patterns of Care and Survival in the Netherlands: A Population-Based Study.
    de Boer NL; van Kooten JP; Damhuis RAM; Aerts JGJV; Verhoef C; Madsen EVE
    Ann Surg Oncol; 2019 Dec; 26(13):4222-4228. PubMed ID: 31620941
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Malignant peritoneal mesothelioma treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: is GLUT1 expression a major prognostic factor? A preliminary study.
    Hommell-Fontaine J; Isaac S; Passot G; Decullier E; Traverse-Glehen A; Cotte E; You B; Mohamed F; Gilly FN; Glehen O; Berger F
    Ann Surg Oncol; 2013 Nov; 20(12):3892-8. PubMed ID: 23800898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Mesothelioma: Experience of a Peritoneal Surface Malignancy Center.
    Aydin N; Sardi A; Milovanov V; Nieroda C; Sittig M; Nunez MF; Jimenez W; Gushchin V
    Am Surg; 2015 Dec; 81(12):1253-9. PubMed ID: 26736164
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.